XenImmune Therapeutics is developing a novel antibody-enzyme fusion to target tumors and trigger the robust immune response known as hyper-acute rejection.
© 2023 Center For Technology Licensing. Ithaca: 395 Pine Tree Road, Suite 310, Ithaca, NY 14850 | 607-254-4698. WCM: 1155 York Avenue, New York, NY 10065 | 646-962-7045. Contact
©️2022 Cornell University. Web Accessibility Assistance | Privacy Policy